Joyani Das, PhD, earned her doctoral degree in pharmacology from the Birla Institute of Technology in Mesra, India, and brings over six years of experience in medical research, education, and health communication. She works as a medical writer, creating evidence-based health content for a broad audience. Prior to this, she worked as a health writer at MomJunction, specializing in health and wellness topics related to women and children. She also served as an associate professor, contributing to academic research and mentoring students in pharmacological sciences. Her areas of expertise include medical writing and drug information.
Recent WebMD content from Joyani Das, PhD
- Kygevvi: FDA Approves First Oral Treatment for Thymidine Kinase 2 Deficiency (TK2d)
- FDA Approves Revuforj as a Targeted Oral Therapy for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
- Gazyva: FDA Approves Antibody-Based Infusion Therapy for Adults With Lupus Nephritis
- Rybelsus: FDA Approves the Only Oral GLP-1 Medicine to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes
- Tezspire: FDA Approves New Option for Chronic Sinus Inflammation With Nasal Polyps
- Uzedy: FDA Approves Once-a-Month Subcutaneous Injectable Risperidone for Bipolar I Disorder
- Zoryve: FDA Expands Use of Once-Daily Steroid-Free Skin Cream for Children Ages 2-5 Years With Mild to Moderate Eczema
- FDA Expands Approval of Simponi for Use in Pediatric Patients with Ulcerative Colitis
- Jascayd: New Oral Therapy for Idiopathic Pulmonary Fibrosis in Adults
- FDA Approves Combined Use of Zepzelca and Atezolizumab as First-Line Maintenance Treatment for Advanced Small-Cell Lung Cancer
- Inluriyo: FDA Approves New Once-Daily Pill for ESR1-Mutated Advanced Breast Cancer in Patients Previously on Hormone Therapy
- FDA Approves Palsonify: First Once-Daily Pill for Acromegaly in Adults
- Tremfya: First Fully Under-the-Skin IL-23 Inhibitor Shot Approved for Ulcerative Colitis and Crohn’s Disease
- Keytruda Qlex: FDA Approves New Subcutaneous Immune Therapy Shot for Treating a Wide Range of Advanced Cancers
- Forzinity: New Once-Daily Shot Gets Accelerated FDA Nod for Boosting Muscle Strength in Barth Syndrome
- FDA Approves Enbumyst: First and Only Nasal Spray Diuretic for Edema From Heart, Liver, and Kidney Diseases
- Opzelura: FDA Expands Use of Steroid-Free Skin Cream for Young Children With Eczema
- Vyjuvek Label Update: FDA Removes Lower Age Limit
- Ocaliva Pulled From U.S. Market for Liver Disease
- Inlexzo: A New Bladder Cancer Treatment
- FDA Expands Approved Use of Vonvendi
- FDA Approves At-Home Once-Weekly Leqembi Injection as Maintenance Therapy for Early Alzheimer's Disease
- Wayrilz: A New Twice-Daily Pill for Chronic Immune Thrombocytopenia Unresponsive to Other Therapies
- FDA Expands Repatha Approval
- Dawnzera: First RNA-Targeted Therapy to Prevent Hereditary Angioedema Attacks
- FDA Approves Wegovy as First Once-Weekly Injection for Obesity-Linked Liver Disease
- FDA Approves New Non-Opioid, Once-Daily Bedtime Tablet for Fibromyalgia Pain and Sleep Disturbance
- Brinsupri: First Once-Daily Tablet for Non-Cystic Fibrosis Bronchiectasis
- Hernexeos (Zongertinib) Approved as the First Oral Targeted Treatment for HER2-Mutant Advanced Lung Cancer
- Ajovy Approved as a First-of-Its-Kind Shot for Preventing Migraine in Children and Teens
